Journal of Physiology and Biochemistry · 12 Nov 2026
A pilot study on the impact of Hydroxiram D supplementation on nutritional status and sarcopenia-related parameters
Paolo Gallo, Valentina Flagiello, Simone Di Cola, Lucrezia Santoro, Dafne Marcelli, Giorgio Reggiardo, Francesca Terracciani, Andrea Falcomatà, Antonio De Vincentis, Antonio Picardi, Raffaele Antonelli-Incalzi, Umberto Vespasiani-Gentiluccih-index 24
Citations by database
Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.
- OpenCitations0
- Crossref0
- Europe PMC0
Citations per year
The current year is still counting.
- 2026 so far0
Abstract
Abstract Sarcopenia is a frequent and prognostically relevant complication of chronic liver disease. The SARCIRAM pilot trial investigated the effect of Hydroxiram D, a formulation of branched-chain amino acids (BCAAs), β-hydroxy-β-methylbutyrate (HMB), and vitamin D, on nutritional status and sarcopenia-related parameters in patients with compensated cirrhosis due to metabolic dysfunction-associated steatotic liver disease (MASLD). In this single-center, randomized pilot study, adults with compensated MASLD-related cirrhosis (Child-Pugh A) received Hydroxiram D plus standard care or standard care alone for 6 months. The primary outcome was phase angle (PA), while secondary outcomes were appendicular skeletal muscle mass (ASMM)/height², handgrip strength (HGS), and 4-meter walk test (4-mWT). Between-group comparisons used baseline-adjusted models. Post-hoc simulation analyses were used exploratorily to inform the design of future studies. Thirty-two patients were analyzed. After 6 months, the adjusted change in PA was significantly more favorable in the treated group versus controls (+ 0.36° vs. − 0.45°, p = 0.046). Between-group differences in muscle mass, HGS, and gait speed were not statistically significant, although effect estimates directionally favoured the intervention. No treatment-related adverse events were observed. Six months of Hydroxiram D was associated with a more favorable change in PA in patients with compensated MASLD-related cirrhosis, with favorable trends in muscle parameters. These hypothesis-generating findings warrant confirmation in larger, prospectively registered, double-blind trials to confirm efficacy and long-term outcomes.
What the data shows
- No database records a citation yet, as is usual for a paper this new.
- Umberto Vespasiani-Gentilucci has the highest h-index among the authors (24).
Graph
This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.
Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.
Start with
Cited by 0 papers
Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.
References (29)
What it cites, from open citation data, with Crossref's record of each.
Sign in to see 9 more references
A free account opens the rest of the citing papers and references on every paper’s page.